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• Preliminary estimates indicate that there were 1,740 drug-induced deaths among
Australians in 2018 (1,549 drug-induced deaths among those aged 15-64 years).
This estimate does not include deaths where conditions related to alcohol or
tobacco were the underlying cause of death.
• This number equates to nearly five drug-induced deaths per day in 2018, a
similar figure to that observed in 2017 (1,795 deaths). It is also similar to the
number recorded during the peak in deaths in 1999 (1,740 deaths).
• The rate of deaths in 2018 was 7.0 deaths per 100,00 people (9.5 deaths per
100,000 people aged 15-64). The rate of drug-induced deaths has been
increasing since 2006 yet remains lower than the peak rate observed in 1999.
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• Higher rates of drug-induced deaths were observed among males, but there has
been a shift from younger (25-34) to older (35-54) age groups over the period of
monitoring across both males and females. The gap in rate of deaths between
males and females lessened with older age in 2018.
• In 2018, the majority of drug-induced deaths among Australians were deemed
accidental (70%), although nearly one-in-five deaths (23%) were considered
intentional.
• Excluding Northern Territory, the rates of drug-induced deaths in all other
jurisdictions ranged between 6.3 and 9.9 per 100,000 people. There are
important jurisdictional differences in drug-induced deaths in major city versus
regional areas, with a higher rate of drug-induced deaths in major cities in
Western Australia and South Australia and in regional areas in New South Wales
and Victoria (noting fluctuations in these trends over time).
• Opioids were the main drug cited in drug-induced deaths (1,129 deaths in 2018).
Indeed, they were noted as the underlying cause of 1,088 deaths (including 876
deaths deemed accidental).
• Natural and semi-synthetic opioids (e.g., morphine, oxycodone) have historically
been the most commonly cited opioids in opioid-induced deaths. This has
changed over the past two years, with the rate of opioid-induced deaths involving
heroin converging with the rate of opioid-induced deaths involving natural and
semi-synthetic opioids.
• When studying accidental deaths only, heroin is now the leading opioid
underlying opioid-induced deaths. There have also been increases in deaths
involving synthetic opioids (e.g., fentanyl, tramadol) over the past decade,
although preliminary estimates do not support a further increase in 2017 and
2018.
• An increasing rate of deaths involving psychotropic medicines (e.g.,
benzodiazepines, antipsychotics) and non-opioid medicines used for treatment
of certain pain conditions (e.g., pregabalin) is of concern. It is important to note
that these medicines are often identified alongside other drugs (e.g., cases
where opioids are the underlying cause of death and benzodiazepines are an
associated cause of death).
• The rate of deaths attributed to amphetamines (e.g., methamphetamine, MDMA)
increased substantially from 2011 to 2016; preliminary estimates do not support
a further increase in 2017 and 2018. The number of cocaine-induced deaths
remained relatively small (i.e., less than 20 deaths).
This bulletin reports on drug-induced deaths (i.e., deaths directly attributable to
drug use) in Australia from 1997-2018 (Panel A). Data were accessed from the
Australian Bureau of Statistics (ABS). Details of the methods are available for
download; this document and the ABS Explanatory Notes should be read
alongside this bulletin.
Data presented here reflect key findings for Australians of all ages unless
otherwise indicated. We also report select findings for Australian adults aged 15-64
years as the population at greatest risk of experiencing these deaths. Small
numbers of deaths have been randomly assigned by ABS to protect the
confidentiality of individuals and may be suppressed where presentation of
trends could be misleading. Zero values have not been affected by
confidentialisation. The ABS undertake a revision process for coroner-certified
deaths over a 3-year period. Accordingly, causes of death data for 2017 and 2018
are preliminary and subject to two further revisions; data for 2016 are revised and
subject to another revision; data for 2015 and earlier years are final.
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Panel A. Terminology
• Underlying cause of death (UCOD) is the disease or condition which
initiated the sequence of events resulting in death. There can be only one
underlying cause of death.
• Associated causes of death (ACOD) are any other diseases or conditions
that contributed to the death and are listed on the death certificate but were
not deemed the underlying cause of death.
• Multiple causes of death (MCOD) include all causes (both underlying and
associated causes), diseases and conditions reported on the death certificate.
• Drug-induced death includes all deaths where the UCOD indicates a
substance-use disorder or direct harm due to selected substances (excluding
alcohol and tobacco).
• Opioid-, amphetamine- and cocaine-induced death includes all deaths
where the UCOD indicates a substance-use disorder or direct harm specific to
that drug.
• Drug-induced death by drug type is where the drug of interest (e.g.,
benzodiazepines) may appear as UCOD or ACOD, noting that there may be
other drugs coded to these fields and there must be a drug coded as UCOD.
For example, a ‘drug-induced death involving benzodiazepines’ could
comprise an opioid as UCOD and a benzodiazepine and alcohol as ACOD..
We provide estimates of drug-induced deaths directly attributable to use of illicit
drugs (e.g., heroin), some prescription medicines (that may be prescribed to the
individual or obtained via other means) and medicines available over-the-counter.
These figures only include deaths where drugs have been deemed the underlying
cause of death (Panel A). We have, however, identified drug-induced deaths
where multiple drugs may also be coded as associated causes of death.
The codes applied to identify cause(s) of death have limited specificity for drugs.
Number of deaths may differ between organisations reporting on deaths due to the
codes used (see our methods document for details of the codes used for our
reporting).
These figures do not include deaths from accidents caused by being under the
influence of a drug (e.g., motor vehicle accident). We have not included deaths
where conditions related to alcohol or tobacco comprise the underlying
cause of death as they fall outside the scope of our monitoring. We
acknowledge the significant loss of life from these substances among Australians,
and encourage readers to refer to the National Alcohol Indicators Project, ABS
reporting and Australian Institute of Health and Welfare reporting for further
information on deaths and other harms related to these substances.
Where possible, we have reported on deaths attributed to opioids, amphetamines,
and cocaine as per previous reporting; that is, where opioids, amphetamines and
cocaine are deemed to be the underlying cause of death (e.g., opioid-induced
deaths; Panel A). It is important to note many drug-induced deaths involve more
than one drug (including alcohol), and sometimes it is not possible to determine
one substance as the underlying cause of death.
We have discussed select trends of interest in the panels (Panel B: trends in drug-
induced deaths involving antipsychotic medicines and Panel C: trends in deaths
involving heroin). An accompanying public online interactive data visualisation also
allows viewers to disaggregate data in many different ways, and to download
these images for their own use. This visualisation allows viewers to look at trends
by drug, jurisdiction, sex, age group, remoteness and intent, and as numbers or
rates per 100,000 or 1,000,000 population with associated confidence intervals.
In 2018, there were 1,740 deaths among Australians (1,549 drug-induced deaths
among those aged 15-64). This equates to 7.0 deaths per 100,00 Australians (9.5
deaths per 100,000 people aged 15-64).
There was a peak in drug-induced deaths in the late 1990s, followed by a decline
in the early-mid 2000s (Figure 1). Since 2006, drug-induced deaths in Australia
have increased. The number of deaths recorded each year from 2014 to 2018 has
been similar to the number observed during the earlier peak in deaths in the late
1990s. By contrast, the rate of drug-induced deaths (adjusting for changes in
population size) was also high in 2018 but has not reached the level observed in
the late 1990s (9.3 versus 7.0 deaths per 100,000 people in 1999 versus 2018).
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The estimated number of drug-induced deaths among Australians did not increase
from 2017 to 2018 (1,795 versus 1,740 deaths or 7.3 deaths versus 7.0 deaths per
100,000 people). Estimates for these years may be subject to revision.
Intent of Drug-Induced Deaths
In 2018, 70% of drug-induced deaths among Australians were considered
accidental and 23% intentional (1,210 versus 400 deaths, respectively; Figure 2).
The rate of accidental drug-induced deaths among Australians has been
consistently higher than that of intentional deaths over the course of monitoring
(4.8 deaths versus 1.6 per 100,000 people in 2018). Undetermined and other
intents comprise the other 7% of drug-induced deaths in 2018.
Age and Sex Profile of Drug-Induced Deaths
In 2018, men comprised a greater percentage of drug-induced deaths relative to
women (64% versus 36%), with 1,116 drug-induced deaths among males and 624
deaths among females (9.0 deaths versus 5.0 deaths per 100,000 people). This
distribution has been relatively consistent over time. The difference in the rate of
drug-induced deaths between males and females lessens in older age groups.
Approximately three-in-four (76%) deaths among males were accidental in 2018
(17% intentional), while 57% of deaths among females were accidental (33%
intentional). This is also consistent with historical data, with drug-induced deaths
among females being more likely to be coded as intentional than deaths among
males.
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Figure 1. Rate (per 100,000 people) and number of drug-induced deaths in 
the Australian population, 1997-2018 
Deaths where conditions related to alcohol or tobacco comprised the underlying cause of death are not captured here. 
Causes of death data for 2016, 2017 and 2018 are not final and subject to further revision.
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Figure 2. Rate (per 100,000 people) of drug-induced deaths in the Australian 
population, by intent, 1997-2018 
Deaths where conditions related to alcohol or tobacco comprised the underlying cause of death are not captured here. 
Causes of death data for 2016, 2017 and 2018 are not final and subject to further revision.
Figure 3. Rate (per 100,000 people) of drug-induced deaths in the Australian 
population, by age group, 1997-2018 
Deaths where conditions related to alcohol or tobacco comprised the underlying cause of death are not captured here. 
Causes of death data for 2016, 2017 and 2018 are not final and subject to further revision.
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In 2018, drug-induced deaths were most common among those aged 35-44 (14.4
deaths per 100,000 people) and aged 45-54 (14.1 per 100,000 people), and least
common amongst those aged 15-24 years (2.6 deaths per 100,000 people).
This represents a shift over time (Figure 3). In the late 1990s, drug-induced
deaths were driven by those in the younger age groups (e.g., 25-34 age group,
followed by 35-44 age group). By contrast, the greatest increase over time was in
the 45-54 age group (5.6 versus 14.1 deaths per 100,000 people in 1997 and
2018, respectively) and 55-64 age group (3.2 versus 9.3 deaths per 100,000 in
1997 and 2018, respectively).
When studying by age group and sex, there has been a similar shift to higher
rates of drug-induced death among men in older age groups (Figure 4). Rates
among women have also shown a similar but less pronounced shift. These age
trends are also mostly driven by accidental deaths; there are no overtly
distinguishable age trends for intentional deaths with the exception of increasing
rates of drug-induced deaths amongst older age groups (i.e., those aged 45 and
older).
Drug-Induced Deaths by Jurisdiction of Usual Residence and
Remoteness Area
In 2018, the largest number of deaths was reported in New South Wales (525
deaths of which 388 were deemed accidental), followed by Victoria (403 deaths
of which 292 were deemed accidental), and Queensland (358 deaths of which
223 were deemed accidental). Excluding Northern Territory, the rate of drug-
induced deaths ranged between 6.3 and 9.9 deaths per 100,000 people.
Figure 4. Rate (per 100,000 people) of drug-induced deaths for Australian 
males and females, by age group, 1997-2018 
Deaths where conditions related to alcohol or tobacco comprised the underlying cause of death are not captured here. 
Causes of death data for 2016, 2017 and 2018 are not final and subject to further revision.
The greater proportion of drug-induced deaths in 2018 occurred in major cities
(72%, 1,217 deaths), followed by inner regional (20%, 345 deaths), outer regional
(7%, 116 deaths), and remote/very remote (1.3%, 22 deaths) areas. These
findings must be considered in the context of differences in population size across
these areas. Indeed, the rate of total drug-induced deaths in 2018 was 7.8, 6.8,
5.7, and 4.5 deaths per 100,000 people in inner regional, major cities, outer
regional and remote/very remote areas, respectively (Figure 5).
There are important jurisdictional differences between major city versus regional
areas, with a higher rate of deaths in 2018 in major cities in Western Australia and
South Australia, and in regional areas in New South Wales and Victoria.
Disaggregation by remoteness is not presented for the Northern Territory,
Tasmania and the Australian Capital Territory due to small numbers. See the online
interactive data visualisation for further jurisdictional findings.
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Drugs Involved in Drug-Induced Deaths
The following findings relate to drugs identified in toxicology reports as being
present in the person’s system and deemed to be contributory to that death. There
may be multiple drugs that contribute to a drug-induced death.
In 2018, opioids were the most common class of drug involved in drug-induced
deaths (1,129 deaths, 4.5 deaths per 100,000 people; Figure 6). This was
followed by antiepileptic, sedative-hypnotic and anti-parkinsonism drugs (990
deaths, 4.0 deaths per 100,000 people), which predominantly comprised
benzodiazepines (883 deaths, 3.5 deaths per 100,00 people).
Figure 5. Rate (per 100,000 people) and number of drug-induced deaths in
the Australian population, by remoteness area, 1997-2018
Deaths where conditions related to alcohol or tobacco comprised the underlying cause of death are not captured here. 
Causes of death data for 2016, 2017 and 2018 are not final and subject to further revision.
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Other commonly cited drugs in 2018 included antidepressants (574 deaths, 2.3
deaths per 100,000 people), amphetamines (407 deaths, 1.6 deaths per 100,000
people), antipsychotics and neuroleptics (371 deaths, 1.5 deaths per 100,000
people), alcohol (337 deaths, 1.4 deaths per 100,000 people), non-opioid
analgesics, antipyretics and antirheumatics (315 deaths, 1.3 deaths per 100,000
people) and cannabinoids (264 deaths, 1.1 deaths per 100,000 people). These
rates are largely consistent when examining drugs involved in accidental deaths
only in 2018.
Whilst opioids continue to be the main drug cited in drug-induced deaths, there are
increasing rates of drug-induced deaths involving other drugs. Rates of any drug-
induced death (and of the subset of accidental drug-induced deaths) have
remained relatively stable or increased from 2017 to 2018 for all drug classes
except for opioids. These rates will likely only increase as coronial cases are
closed and cause of death is finalised. Indeed, excluding opioids and alcohol, the
rates for all deaths (and of the subset of accidental drug-induced deaths) have
increased for all drug classes since the mid-to-late 2000s, and are now higher than
observed in the late 1990s when there was a peak in drug-induced deaths.
Figure 6. Rate (per 100,000 people) of drug-induced deaths in the Australian
population, by drug type, 1997-2018
Note that one drug-related death may involve multiple drugs and that findings here reflect the rate of drug-induced deaths
involving each drug (not necessarily attributed solely to that drug). Deaths where conditions related to alcohol or tobacco
comprised the underlying cause of death are not captured here. Causes of death data for 2016, 2017 and 2018 are not
final and subject to further revision.
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Particular increases have been observed in the rate of deaths involving certain
psychotropic medicines (see Panel B). For example, the rate of deaths involving
benzodiazepines increased from 2008 to 2018 from 1.9 to a peak of 3.5 deaths per
100,000 people (402 to 883 deaths). It is important to note that these drugs may not
necessarily be coded as the underlying cause of death and often occur in the
context of polysubstance use. For example, 693 deaths in which opioids were
deemed the underlying cause of death in 2018 also had benzodiazepines coded as
a contributory cause of death. Similarly, there was a total of 171 drug-induced
deaths identified in 2018 as involving ‘antiepileptic and sedative-hypnotic drugs
unspecified’ (predominantly comprising pregabalin). Yet, 144 deaths in which
opioids were deemed the underlying cause of death also had pregabalin coded as a
contributory cause, suggesting that the majority of drug-induced deaths involving
pregabalin arose in the context of opioid use.
Deaths Attributed to Opioids
The following findings relate to ‘opioid-induced deaths’; that is, those directly
attributable to use of opioids (e.g., from opioid overdose).
In 2018, there were 1,088 opioid-induced deaths among Australians (4.4 deaths per
100,000 people). This is compared to 1,227 and 1,153 opioid-induced deaths in
2016 and 2017 (5.1 and 4.7 deaths per 100,000 people), respectively, whilst noting
that these numbers are subject to revision, and anticipated to increase as coronial
cases are closed in the coming two years.
Intent, age and sex of opioid-induced deaths
The majority (81%, 876 deaths) of opioid-induced deaths in 2018 were considered
accidental; 15% (168 deaths) were intentional; and a minority (4%, 44 deaths)
deemed of undetermined intent. This pattern has been relatively consistent over
recent years.
The rate of opioid-induced deaths has been consistently higher among men than
women over time, with 6.0 versus 2.8 deaths per 100,000 people (741 versus 347
deaths) among males and females, respectively, in 2018. This pattern is also
evident when studying specifically accidental opioid-induced deaths. By contrast,
females have had a greater rate of intentional opioid-induced deaths relative to
males in recent years (0.7 versus 0.6 deaths per 100,000 people in 2018,
respectively), although this has varied over time.
In 2018, the rate of opioid-induced deaths was highest for Australians aged 35-44
years (10.0 per 100,000 people, 333 deaths). The lowest rates remain among
Australians younger than 25 or older than 65 years. Particular increases have been
observed in the rate of opioid-induced deaths among the 45-54 and 55-64 age
groups over the last 10 years of monitoring.
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Panel B. Involvement of antipsychotics in drug-related deaths in Australia
Various antipsychotic medicines are listed under the Pharmaceutical Benefits
Scheme for subsidy for the treatment of certain psychiatric conditions including
psychosis and bipolar disorder. Prescribing of antipsychotics (e.g., quetiapine,
olanzapine, risperidone) has increased over time in Australia, and there are reports
of certain medicines being used off-label for indications where the evidence
balancing benefits/risks is less clear (e.g., use of quetiapine to manage insomnia
and anxiety). Extra-medical use (i.e. use outside the bounds of a doctor’s
prescription) and associated harms (e.g., overdose) have been documented.
Our analyses show that the rate of drug-induced deaths involving 'antipsychotic
and neuroleptic medicines' remained relatively low until 2014, ranging between 0.3
and 0.6 deaths per 100,000 people (Figure B). The rate then increased to a peak
of 1.5 deaths per 100,000 people in 2018, with 371 deaths involving antipsychotic
and neuroleptic medicines recorded in that year. This trend was driven by ‘other
and unspecified antipsychotics’ (predominantly comprising quetiapine). In 2018,
there were 262 deaths attributed to opioids where 'antipsychotic and neuroleptic
medicines' were coded as an associated cause of death, suggesting that
combined use of these substances was common.
Figure B. Rates (per 100,000 people) of drug-induced deaths involving antipsychotic medicines and 
of opioid-induced deaths involving antipsychotic medicines among Australians, 1997-2018 
These rates are not adjusted for prescribing trends. Regardless, these findings
highlight the need to ensure people are aware of the risks associated with use of
antipsychotic medicines (particularly when consumed with opioids). Strategies to
reduce harm must be weighed against the risk of restricting access to those who
require these medicines, namely those with psychosis or bipolar disorder.
Types of opioids and other drugs involved in opioid-induced deaths
In 2018, 30% (322 deaths) of opioid-induced deaths were attributed to illicit opioids
only (e.g., heroin, opium), 60% (655 deaths) were attributed to pharmaceutical
opioids only (including methadone), and 10% (108 deaths) to both pharmaceutical
opioids and illicit opioids. This represents an increase since 2014, when 17% of
deaths were attributed to illicit opioids only, 75% to pharmaceutical opioids only,
5% to illicit and pharmaceutical opioids, and the remaining 3% to other and
unspecified opioids.
In 2018, there were 462 opioid-induced deaths involving natural and semi-
synthetic opioids (e.g., morphine, codeine, and oxycodone), 430 deaths involving
heroin, 230 deaths involving synthetic opioid opioids (e.g., fentanyl, tramadol,
pethidine), and 218 deaths involving methadone (these numbers are not additive
as multiple opioids may be involved in a single opioid-induced death). This is
equivalent to rates of 1.9, 1.7, 0.9, and 0.9 deaths per 100,000 people,
respectively.
Natural and semi-synthetic opioids (e.g., morphine, oxycodone) have historically
been the most commonly cited opioids in opioid-induced deaths. This has changed
over the past two years. The rate of deaths involving heroin has converged on the
rate and, in the case of accidental deaths, exceeded the rate observed for natural
and semi-synthetic opioids (Figure 7; see Panel C). Indeed, there were 1.6
accidental deaths involving heroin versus 1.2 accidental deaths involving natural
and semi-synthetic opioids per 100,000 people (396 versus 310 deaths) in 2018.
There had been an increase in the rate of deaths involving synthetic opioids over
the past decade, although preliminary estimates do not support a further increase
in 2017 and 2018.
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Figure 7. Rate (per 100,000 people) of opioid-induced deaths in the
Australian population, by intent and opioid type, 1997-2018
Opioid-induced deaths comprised deaths where the underlying cause of death indicates a substance-use disorder or direct
harm specific to opioids. Note that one opioid-induced death may involve multiple opioids. Causes of death data for 2016,
2017 and 2018 are not final and subject to further revision.
Panel C. Trends in heroin-related deaths in Australia
There has been recent concern around increasing use and harms associated with
heroin in Australia, particularly in certain areas. Whilst analyses of drug seizure
and arrest data suggest the heroin market remains small and stable, wastewater
analyses show an increase in heroin from August 2017 to April 2019 (with some
variation), and particular increases in capital cities in Victoria and New South
Wales. Research with sentinel samples of people who inject drugs shows notable
differences in the use of heroin across samples drawn from different capital cities
but also that around 12% of people sampled in 2019 reported a past 12-month
non-fatal heroin overdose. There is also evidence of increasing heroin-related
ambulance attendances in certain jurisdictions.
The current data from Australia show that there were 438 drug-induced deaths
that involved heroin in 2018; heroin was deemed the underlying cause of death in
430 of these cases.
The rate of opioid-induced deaths involving heroin has increased by 2 times in the
past decade from 0.8 deaths per 100,000 people in 2008 to 1.7 per 100,000 in
2018. This equates to a difference or an increase by 0.9 deaths per 100,000
people. This is the highest change in the ten years from 2008 to 2018 among the
opioid types reported in this bulletin. The rates of heroin and of natural and semi-
synthetic opioid death have converged, and the percentage of deaths involving
heroin only relative to pharmaceutical opioids only has increased in recent years.
There are also important jurisdictional differences to acknowledge. In 2018, rates
of drug-induced deaths involving heroin occurred at 3.2 deaths per 100,000
people (82 deaths) in Western Australia, 2.6 deaths per 100,000 people (167
deaths) in Victoria, 1.3 deaths per 100,000 people (105 deaths) in New South
Wales and 1.0 deaths per 100,000 people (49 deaths) in Queensland. Tasmania,
South Australia, the Australian Capital Territory and the Northern Territory
recorded 20 or fewer drug-induced deaths involving heroin in 2018.
There is under-reporting of deaths involving heroin in the data used here. We also
encourage the reader to view recent work exploring characteristics of
pharmaceutical opioid versus heroin-induced deaths in Australia.
These findings, however, reinforce the necessity of close ongoing monitoring of
heroin use and associated harms in Australia. They also highlight the need to
proactively maximise coverage of known effective interventions to reduce
overdose risk (e.g., opioid agonist treatment, naloxone provision), and to move
away from strategies shown to increase harm (e.g., criminalisation of drug use).
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Deaths Attributed to Amphetamines
There were 99 amphetamine-induced deaths among Australians in 2018 (0.4
deaths per 100,000 people). The rate of amphetamine-induced deaths increased
substantially from 2011 (22 deaths, 0.1 deaths per 100,000 people) to 2016 (106
deaths, 0.4 deaths per 100,000 people). The preliminary estimates of
amphetamine-induced deaths in 2017 and 2018 do not represent a further
increase on this rate (0.4 per 100,000 people in both years, or 94 and 99 deaths,
respectively).
Data provided do not allow for reliable disaggregation of deaths due to
methamphetamine versus 3,4-methylenedioxymethamphetamine (MDMA).
Deaths Attributed to Cocaine
In 2018, there were fewer than 20 cocaine-induced deaths among Australians.
This low number is consistent with previous years.
The Drug Trends program is funded by the Australian Government Department of
Health under the Drug and Alcohol Program.
Thanks to Lauren Moran and Nathan Bonamy of the Australian Bureau of
Statistics for their assistance with the data provided for this bulletin.
Man, N., Chrzanowska, A., Dobbins, T., Degenhardt, L. & Peacock, A. (2019).
Trends in drug-induced deaths in Australia, 1997-2018. Drug Trends Bulletin
Series. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney.
• Deaths data visualisations: https://drugtrends.shinyapps.io/deaths_2018
• Deaths methods document: https://ndarc.med.unsw.edu.au/resource/trends-
drug-induced-deaths-australia-1997-2018
• For information on drug-related hospitalisations in Australia, go to: 
https://ndarc.med.unsw.edu.au/resource/trends-drug-related-hospitalisations-
australia-1999-2018
• For more information on NDARC research, go to: http://ndarc.med.unsw.edu.au/
• For more information about the ABS, go to: http://www.abs.gov.au
• For more information on ICD coding go to: 
http://www.who.int/classifications/icd/en/
• For more research from the Drug Trends program go to: 
https://ndarc.med.unsw.edu.au/program/drug-trends
Email: drugtrends@unsw.edu.au
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